Connect Biopharma Holdings Limited CNTB
Regular-session close
After hours · Nov 20, 7:25 PM ET
- YTD
- -79.08%
- 1 year
- -81.27%
5D -0.0600 (-8.82%)
- Market cap
- 38.05M
- Revenue (ttm)
- 24.12M
- Profit margin
- -88.66%
- EPS (ttm)
- -1.19
- Shares out
- 55.25M
- Forward P/E
- -5.04
- YTD return
- -79.08%
- 1-year return
- -81.27%
- Volume
- 365.98K
- Avg volume
- 3.99M
- Open
- 0.62
- Previous close
- 0.6282
- Day's range
- 0.5897 – 0.6378
- 52-week range
- 0.579 – 3.69
- Beta
- -0.31
- Price target
- 7.00 (+1086.4%)
Key statistics
- 50-day average
- 1.12
- 200-day average
- 1.34
- Enterprise value
- -57.37M
- Price / sales
- 2.31
- Price / book
- 0.50
- Free cash flow
- -17.08M
- Total cash
- 110.24M
- Total debt
- 325.00K
- Return on equity
- -17.92%
- Short % of float
- 0.18%
Fundamental scorecard
4 of 25 checks passed on CNTB’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 30, 2023 | Dec 1, 2022 | -0.48 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 17, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 4, 2024 | HC Wainwright & Co. | init | — | Buy |
| Sep 13, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Feb 8, 2023 | SVB Leerink | main | — | Outperform |
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- connectbiopharm.com
News
Piper Sandler Maintains Overweight on Connect Biopharma Hldgs, Lowers Price Target to $5
Connect Biopharma Hldgs Q3 EPS $(0.26) Beats $(0.27) Estimate, Sales $736.000K Miss $771.429K Estimate
Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
Your note
Sign in to keep a note on CNTB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 3.79% | 2,093,232 | 2.11M | Sep 29, 2024 |
| O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 0.92% | 510,701 | 514.48K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.32% | 175,500 | 176.80K | Sep 29, 2024 |
| Callan Capital LLC | 0.08% | 41,823 | 42.13K | Sep 29, 2024 |
| Keudell/Morrison Wealth Management | 0.06% | 33,450 | 33.70K | Sep 29, 2024 |
| Royal Bank of Canada | 0.06% | 30,600 | 30.83K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 27,961 | 28.17K | Oct 30, 2024 |
